Correspondence | Published:

Overhauling the reimbursement system for molecular diagnostics

Nature Biotechnology volume 29, pages 390391 (2011) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Nat. Biotechnol. 28, 1157–1159 (2010).

  2. 2.

    & Health Policy 94, 91–100 (2010).

  3. 3.

    , & J. Oncol. Pract. 6, 238–242 (2010).

  4. 4.

    Anonymous. The New Science of Personalized Medicine: Translating the Promise into Practice (PricewaterhouseCoopers, 2009).

  5. 5.

    & Pharmacoeconomics 28, 153–162 (2010).

  6. 6.

    & Health Aff. 25, 1218–1230 (2006).

  7. 7.

    The impact of CED on private payers. Biotechnology Healthcare 24–30 (April 2007).

  8. 8.

    Kaiser Family Foundation. Kaiser Slides: Medicare Enrolment, 1966–2010 <> (Accessed 26 January 2011).

  9. 9.

    & The Gray Sheet (28 June 2010).

  10. 10.

    PricewaterhouseCoopers. Diagnostics 2009: Moving Towards Personalised Medicine (PricewaterhouseCoopers, 2009).

  11. 11.

    The Lewin Group. The Value of Diagnostics Innovation, Adoption and Diffusion into Health Care (The Lewin Group, 2005).

  12. 12.

    Nat. Biotechnol. 26, 509–517 (2008).

Download references

Author information

Affiliations

  1. Institute of Biotechnology, University of Cambridge, Cambridge, UK.

    • Nafees N Malik

Authors

  1. Search for Nafees N Malik in:

Competing interests

N.N.M. presently works for GlaxoSmithKline, but the correspondence is based on work done at the University of Cambridge.

Corresponding author

Correspondence to Nafees N Malik.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1869

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing